EGFR and non-small cell lung carcinoma: Of interest, EGFR inhibitors are currently used in clinics for non-small cell lung cancer patients with EGFR activating mutations [28,29,30,31] and RAB25 expression has been reported to correlate positively with EGFR inhibitor sensitivity in NSCLC cell lines [32].